Cutting Through the Confusion: A Look at Guidelines and Emerging Treatments for Chronic Spontaneous Urticaria
Adaptive LearningPremiere Date: Friday, March 18, 2022
This activity offers CE credit for:%>
- ABIM (MOC)
- Medicine (accme)
- Nursing (ANCC)
- Pharmacy (acpe)
- PA (aapa)
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Saturday, March 18, 2023
|Jason Kihyuk K. Lee, MD, FRCPC, FAAAAI, FACAAI
CEO of Evidence Based Medical Educator Inc.
Chair of Urticaria Canada
Chronic Spontaneous Urticaria (CSU) is largely underdiagnosed and undertreated, leaving many patients with significant quality of life (QoL) impairments. CSU is defined by itchy and sometimes painful hives and/or deep swelling of the skin presenting for six weeks or longer, without an inducible trigger. Despite the impact CSU exacts on QoL, less than half of patients living with CSU achieve complete symptom control with available therapies. Clinicians often struggle to provide guideline-recommended care for CSU patients, with much unknown about its etiology and limited treatment options available. However, recent advances in the understanding of CSU pathophysiology have fueled the creation of new international guidelines and an exponential increase in the number of agents in clinical development for treatment of CSU.
Join Dr. Jason K. Lee in this adaptive learning activity as he contextualizes the latest research in CSU pathophysiology, diagnostic guidelines, and emerging biologic therapies for clinical practice.
At the end of this CE activity, participants should be able to:
- Recognize the pathophysiology of CSU.
- Implement guideline-recommended strategies to effectively manage patients with CSU.
- Interpret the latest clinical data on current and emerging agents for CSU.
Supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals
Physicians, nurse practitioners, PAs, and pharmacists specializing in dermatology and/or allergy/immunology
ABIM MOC Credit:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Royal College MOC:
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.
MIPS Improvement Activity:
This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.
Dr. Lee reports the following financial relationships:
Consultant: AstraZeneca; GlaxoSmithKline; Medexus Pharmaceuticals, Inc.; Muvopharma; Novartis; Regeneron Pharmaceuticals Inc.; Sanofi; and Takeda Pharmaceutical Company Limited
Research Support:AstraZeneca; GlaxoSmithKline; Novartis; Regeneron Pharmaceuticals Inc.; Sanofi; and Takeda Pharmaceutical Company Limited
Speakers Bureau: AstraZeneca; GlaxoSmithKline; Novartis; Regeneron Pharmaceuticals Inc.; Sanofi; and Takeda Pharmaceutical Company Limited
The following Peer Reviewer and CME Outfitters staff reports no financial relationships:
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).